Microbial platform technology for recombinant antibody fragment production: A review

Abstract

Recombinant antibody fragments are being used for the last few years as an important therapeutic protein to cure various critical and life threatening human diseases. Several expression platforms now days employed for the production of these recombinant fragments, out of which bacterial system has emerged a promising host for higher expression. Since, a small antibody fragment unlike full antibody does not require human-like post-translational modification therefore it is potentially expressed in prokaryotic production system. Recently, small antibody fragments such as scFvs (single-chain variable fragments) and Fabs (antibody fragments) which does not require glycosylation are successfully produced in bacteria and have commercially launched for therapeutic use as these fragments shows better tissue penetration and less immunogenic to human body compared to full-size antibody. Recently developed Wacker’s ESETEC secretion technology is an efficient technology for the expression and secretion of the antibody fragment (Fab) exceeded up to 4.0 g/L while scFv up to 3.5 g/L into the fermentation broth. The Pfenex system and pOP prokaryotic expression vector are another platform used for the considerably good amount of antibody fragment production successfully. In this review, we summarize the recent progress on various expression platforms and cloning approaches for the production of different forms of antibody fragments in E. coli.

Keywords:

• Antibody fragments
• bacterial platform
• POP expression vector
• recombinant antibody
• secretary system

Acknowledgements

The authors acknowledge the support received by Ipca Laboratories Ltd., Mumbai, India, and M.D. University, Rohtak, India, for writing this review.

Disclosure statement

The authors report no declarations of interest. The authors also acknowledge the support from SERB, Department of Science and Technology (DST), Government of India (DST Fast Track Grant No. SR/FT/LS-31/2012) and University Grants Commission (UGC), New Delhi, India (Grant No. 42-457/2013(SR)).